23:07 , Sep 19, 2018 |  BC Extra  |  Company News

Management tracks: GSK adds Corsico, Enzmann to chair CHMP

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) hired Chris Corsico, CMO of Boehringer Ingelheim GmbH (Ingelheim, Germany), to lead all development activities for the pharma. As SVP development, Corsico will be based at GSK’s R&D hub in Stevenage,...
23:27 , Jun 14, 2018 |  BC Innovations  |  Tools & Techniques

Imaging immunotherapy

Stanford University researchers have made an imaging agent that detects activated T cells and could predict whether a patient will respond to immunotherapy within days of treatment. Typically, it takes weeks to months to determine...
18:06 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Mouse studies suggest a fusion protein-based vaccine plus a STING-activating cyclic dinucleotide (CDN) adjuvant could help prevent tuberculosis (TB). The fusion protein consists of five Mycobacterium tuberculosis antigens: fbpB, esxA, hrp1, rpfD and Rv1733c....
14:10 , Apr 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Sensor sensibility

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...
15:19 , Mar 30, 2018 |  BC Week In Review  |  Financial News

Versant launches Tempest with $70M

Immuno-oncology company Tempest Therapeutics Inc. (San Francisco, Calif.) emerged from Versant Ventures' Inception Sciences Inc. incubator on March 28 with a tranched $70 million series B led by Versant, F-Prime Capital and Quan Capital. Lilly...
11:04 , Mar 28, 2018 |  BC Extra  |  Financial News

Versant launches Tempest with $70M

Immuno-oncology company Tempest Therapeutics Inc. (San Francisco, Calif.) emerged from Versant Ventures' Inception Sciences Inc. incubator with a tranched $70 million series B led by Versant, F-Prime Capital and Quan Capital. Lilly Asia Ventures, Foresite...
00:19 , Mar 7, 2018 |  BC Extra  |  Company News

Management tracks: Alliance, Anika

Alliance Pharma plc (LSE:APH) said CEO John Dawson will step down, effective May 1. He will be succeeded by Deputy CEO Peter Butterfield. The company also said Chairman Andrew Smith has stepped down. Smith is...
01:24 , Jan 18, 2018 |  BC Extra  |  Preclinical News

Chromosomal instability can trigger metastasis via STING activity

A paper published in Nature brings into question the safety and efficacy of activating the transmembrane protein 173 (STING; TMEM173) pathway -- which triggers immune responses in the presence of cytosolic DNA -- in cancers...
01:21 , Jan 12, 2018 |  BC Innovations  |  Translation in Brief

In the twenties

A Cancer Cell study from University of Southampton and Celldex Therapeutics Inc. (NASDAQ:CLDX) researchers suggests combining CD27 agonists with tumor-targeting mAbs could help myeloid cells attack a broad array of cancers. The partners are testing...
23:21 , Jan 9, 2018 |  BC Extra  |  Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...